/RENB
RENB Stock - Lunai Bioworks Inc.
Healthcare|BiotechnologyNASDAQ
$1.42+0.00%
+$0.00 (+0.00%) • Sep 30
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.99
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RENB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.41 – $1.43
TARGET (TP)$1.63
STOP LOSS$1.31
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.53
52W High$21.00
52W Low$1.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-121,859 | $-113,496 | $-123,590 | $-391,416 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-188,966,000 | $-81,639,296 | $-38,556,891 | $-116,079,191 | $-23,401,787 |
| Net Income | $-178,007,489 | $-80,650,172 | $-39,684,056 | $-113,433,392 | $-26,723,607 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.08 | $-8.40 | $-7.10 | $-21.60 | $-5.70 |
Company Overview
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RENBBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$0.13
Q4 2025
EPS Surprise History
Q1 24
No data
Q3 24
No data
Q4 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $0.13 | — | — |
Q3 2025 | Sep 29, 2025 | — | $-0.77 | — | — |
Q2 2025 | May 15, 2025 | — | $0.01 | — | — |
Q1 2025 | Feb 19, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.03 | — | — |
Q4 2024 | Oct 10, 2024 | — | $-0.45 | — | — |
Q3 2024 | Jul 19, 2024 | — | $-1.58 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.07 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.14 | — | — |
Q3 2023 | Aug 25, 2023 | — | $-3.64 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.08 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.80 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-1.40 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-17.02 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-1.18 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-1.26 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-1.99 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-3.70 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.86 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.63 | — | — |
Latest News
Lunai Bioworks Adopts New Corporate Identity, To Trade Under New Ticker Symbol "LNAI" On Nasdaq Capital Market, Effective Sept 30
➖ NeutralBenzinga•Sep 30, 2025, 01:43 PM•Also:
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 30, 2025, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 29, 2025, 11:50 PM
Lunai Bioworks shares are trading lower . The company recently announced a 10-for-1 reverse stock split.
📉 NegativeBenzinga•Sep 25, 2025, 05:42 PM
Lunai Bioworks Announces 10-For-1 Reverse Stock Split, Effective September 30, 2025
📉 NegativeBenzinga•Sep 24, 2025, 08:51 PM
Lunai Bioworks Subsidiary BioSymetrics Wins $1.85M NIH Grant To Advance AI-Powered Alcohol Use Disorder Drug Discovery
📈 PositiveBenzinga•Sep 11, 2025, 11:07 AM
Lunai Bioworks Launches AI Platform Embedding Biological Risk Intelligence To Accelerate Drug Discovery And Enhance Biodefense Against AI-Designed Toxins
📈 PositiveBenzinga•Sep 9, 2025, 12:48 PM
Lunai Bioworks Reaffirms Long-Term Commitment To European Markets And Partnerships Amid Bankruptcy Of Subsidiary Gedi Cube
➖ NeutralBenzinga•Sep 8, 2025, 12:53 PM
Lunai Bioworks DBA Renovaro Partners With American Defense International To Advance AI-Powered Countermeasures Against Chemical And Biological Threats, Including Highly Toxic Agents Such As Sarin Nerve Gas
📈 PositiveBenzinga•Sep 4, 2025, 02:09 PM
Renovaro shares are trading higher. The company announced it will change its corporate name to Lunai Bioworks Inc.
📈 PositiveBenzinga•Aug 27, 2025, 07:33 PM
Renovaro To Change Its Corporate Name To Lunai Bioworks Inc., Reflecting Strategic Direction In AI-Powered Biodefense, Drug Discovery And Advanced Diagnostics
📈 PositiveBenzinga•Aug 27, 2025, 01:47 PM
Frequently Asked Questions about RENB
What is RENB's current stock price?
Lunai Bioworks Inc. (RENB) is currently trading at $1.42 per share. The stock has moved +0.00% today.
What is the analyst price target for RENB?
No analyst price targets are currently available for this stock.
What sector is Lunai Bioworks Inc. in?
Lunai Bioworks Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RENB's market cap?
Lunai Bioworks Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does RENB pay dividends?
No, Lunai Bioworks Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLK
Allakos Inc.
$0.33
Mkt Cap: $0.0B
ANGN
Angion Biomedica Corp.
$1.00
Mkt Cap: $0.0B
FRLN
Freeline Therapeutics Holdings plc
$6.49
Mkt Cap: $0.0B
GRCE
Grace Therapeutics, Inc.
$3.40
Mkt Cap: $0.0B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
MRNS
Marinus Pharmaceuticals, Inc.
$0.55
Mkt Cap: $0.0B
ORKA
Oruka Therapeutics, Inc.
$31.84
Mkt Cap: $1.2B
SER
Serina Therapeutics, Inc.
$2.75
Mkt Cap: $0.0B
STSA
Satsuma Pharmaceuticals, Inc.
$1.10
Mkt Cap: $0.0B
Explore stocks similar to RENB for comparison